These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25039982)

  • 1. Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer.
    Preusser M; Streubel B; Berghoff AS; Hainfellner JA; von Deimling A; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; Zielinski C; Birner P
    Histopathology; 2014 Nov; 65(5):684-92. PubMed ID: 25039982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High rate of FGFR1 amplifications in brain metastases of squamous and non-squamous lung cancer.
    Preusser M; Berghoff AS; Berger W; Ilhan-Mutlu A; Dinhof C; Widhalm G; Dieckmann K; Wöhrer A; Hackl M; von Deimling A; Streubel B; Birner P
    Lung Cancer; 2014 Jan; 83(1):83-9. PubMed ID: 24183471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
    Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
    Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
    Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
    Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor.
    Schiefer AI; Mesteri I; Berghoff AS; Haitel A; Schmidinger M; Preusser M; Birner P
    Histopathology; 2015 Dec; 67(6):799-805. PubMed ID: 25847631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
    Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
    Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MET Gene Amplification and Overexpression in Chinese Non-Small-Cell Lung Cancer Patients Without EGFR Mutations.
    Song Z; Wang X; Zheng Y; Su H; Zhang Y
    Clin Lung Cancer; 2017 Mar; 18(2):213-219.e2. PubMed ID: 28322191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
    Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
    Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.
    Wang M; Liang L; Lei X; Multani A; Meric-Bernstam F; Tripathy D; Wu Y; Chen H; Zhang H
    Ann Diagn Pathol; 2018 Aug; 35():69-76. PubMed ID: 29843069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of ALK gene rearrangement in non-small cell lung cancer: a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization with correlation of ALK protein expression.
    Kim H; Yoo SB; Choe JY; Paik JH; Xu X; Nitta H; Zhang W; Grogan TM; Lee CT; Jheon S; Chung JH
    J Thorac Oncol; 2011 Aug; 6(8):1359-66. PubMed ID: 21587085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma.
    Mesteri I; Schoppmann SF; Preusser M; Birner P
    Eur J Cancer; 2014 May; 50(7):1354-60. PubMed ID: 24565853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
    Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
    J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
    Schildhaus HU; Schultheis AM; Rüschoff J; Binot E; Merkelbach-Bruse S; Fassunke J; Schulte W; Ko YD; Schlesinger A; Bos M; Gardizi M; Engel-Riedel W; Brockmann M; Serke M; Gerigk U; Hekmat K; Frank KF; Reiser M; Schulz H; Krüger S; Stoelben E; Zander T; Wolf J; Buettner R
    Clin Cancer Res; 2015 Feb; 21(4):907-15. PubMed ID: 25492085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
    Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
    J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of hepatocyte growth factor and c-Met in non-small-cell lung cancer and association with lymphangiogenesis.
    Zhang N; Xie F; Gao W; Yu S; Qiu L; Lin W; Sun Y; Jia T
    Mol Med Rep; 2015 Apr; 11(4):2797-804. PubMed ID: 25504327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
    Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
    Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of p53 protein and p21(WAF1) in non-small-cell lung carcinoma].
    Zhang H; Lü F; Yue W; Yan H; Deng L; Wang S
    Zhonghua Bing Li Xue Za Zhi; 2000 Oct; 29(5):328-30. PubMed ID: 11866928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.